{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T18:38:38Z","timestamp":1776278318245,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The greater predisposition to infections, as well as the possibility of a worse response to treatment, can lead to the excessive use of antimicrobials among cancer patients. C-reactive protein (CRP) has gained prominence as a tool for monitoring therapeutic responses and reducing the duration of antibiotic therapy; however, few studies have analyzed this protein in cancer patient populations. We hypothesize that cancer patients with a good response to antibiotic therapy show a faster decline in serum CRP levels, which would allow us to identify candidates for short-course treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the behavior of serum CRP levels among adult cancer patients using antibiotic therapy, and its association with the duration of this treatment, therapeutic response, and clinical recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This work consisted of a retrospective study with cancer patients admitted to a university hospital between September 2018 and December 2019. Adults (age\u2009\u2265\u200918\u00a0years) who underwent at least one course of antibiotic therapy were included. CRP behavior over the first 7\u00a0days of treatment was classified as: i) good response: when the CRP value on the fifth day of therapy reached 50% or less of the peak value detected in the first 48\u00a0h of treatment, and ii) poor response: Maintenance, within the same interval, of a CRP value\u2009&gt;\u200950% of the peak value in the first 48\u00a0h. The duration of antibiotic therapy was categorized as up to seven full days or more. Outcomes were assessed by events that occurred during the 30\u00a0days of hospitalization or until hospital discharge. Primary outcome: Clinical recurrence of the index infection. Secondary outcomes: i) Death from any cause; ii) microbiological recurrence; iii) therapeutic response; iv) colitis associated with <jats:italic>Clostridioides difficile<\/jats:italic>; and v) isolation of multi-resistant bacteria, whether in clinical or surveillance samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The final analysis consisted of 212 patients, with a median age (IQ) of 59.2 (48 \u2013 67) years old and a predominance of females (65%), who were hypertensive (35%), smokers (21%), and diabetics (17.8%). There was no difference in clinical recurrence between the two groups (8.1% vs. 12.2%; <jats:italic>p<\/jats:italic>\u2009=\u20090.364), with a lower 30-day mortality in the good CRP response group (32.2% vs. 14.5%; <jats:italic>p<\/jats:italic>\u2009=\u20090.002). Despite the tendency towards a lower occurrence of other secondary outcomes in the good response group, these differences were not statistically significant. In the poor CRP response group, outcomes like clinical recurrence, mortality, and therapeutic response were significantly worse, regardless of the duration of antibiotic treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this study, cancer patients with a good CRP response during antibiotic therapy presented lower mortality and a higher proportion of satisfactory therapeutic responses. CRP can be a useful tool when combined with other clinical information in optimizing the duration of antimicrobial treatment in a hospitalized cancer population.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09544-1","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T14:03:02Z","timestamp":1726236182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Significant drop in serum C-reactive protein in patients with solid neoplasia and bacterial infection is associated with a better prognosis and identifies candidates for short-course antibiotic therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Guilherme Monteiro","family":"de Barros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabela Nascimento","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia G\u00f3mez","family":"Ravetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Henrique","family":"Diniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Rosa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara Hemerly","family":"De Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Get\u00falio H.","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandack","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the \u201cN\u00facleo Interdisciplinar de Investiga\u00e7\u00e3o em Medicina Intensiva\u201d (NIIMI)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Vassalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Vin\u00edcius","family":"de Melo Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella Santana","family":"dos Anjos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo Gustavo","family":"Oliveria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciana","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitoria","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Sartorelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"9544_CR1","doi-asserted-by":"publisher","unstructured":"ECDC\/EMEA JOINT TECHNICAL REPORT The bacterial challenge: time to react. EMEA\/576176\/2009; ISBN 978\u201392\u20139193\u2013193\u20134; https:\/\/doi.org\/10.2900\/2518.","DOI":"10.2900\/2518"},{"issue":"9","key":"9544_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938.PMID:28604925;PMCID:PMC5710569","volume":"177","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 2017;177(9):1308\u201315. https:\/\/doi.org\/10.1001\/jamainternmed.2017.1938.PMID:28604925;PMCID:PMC5710569.","journal-title":"JAMA Intern Med"},{"key":"9544_CR3","unstructured":"United Nations Environment Programme. Bracing for Superbugs: Strengthening environmental action in the One Health response to antimicrobial resistance. Geneva; 2023. ISBN: 978-92-807-4006-6."},{"key":"9544_CR4","doi-asserted-by":"publisher","unstructured":"Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrob Agents Chemother. 2018;62(9):e00635\u201318. https:\/\/doi.org\/10.1128\/AAC.00635-18.","DOI":"10.1128\/AAC.00635-18"},{"issue":"10","key":"9544_CR5","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/jac\/dkt177","volume":"68","author":"N Eliakim-Raz","year":"2013","unstructured":"Eliakim-Raz N, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection\u2013 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2013;68(10):2183\u201391. https:\/\/doi.org\/10.1093\/jac\/dkt177.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"9544_CR6","first-page":"CD007577","volume":"2015","author":"R Pugh","year":"2015","unstructured":"Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015;2015(8):CD007577.","journal-title":"Cochrane Database Syst Rev."},{"key":"9544_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12325-020-01558-w","volume":"38","author":"P Moniz","year":"2021","unstructured":"Moniz P, Coelho L, P\u00f3voa P. Antimicrobial Stewardship in the Intensive Care Unit: The Role of Biomarkers, Pharmacokinetics, and Pharmacodynamics. Adv Ther. 2021;38:164\u201379. https:\/\/doi.org\/10.1007\/s12325-020-01558-w.","journal-title":"Adv Ther"},{"issue":"2","key":"9544_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00134-022-06956-y","volume":"49","author":"P P\u00f3voa","year":"2023","unstructured":"P\u00f3voa P, Coelho L, Dal-Pizzol F, Ferrer R, Huttner A, Conway Morris A, Nobre V, Ramirez P, Rouze A, Salluh J, Singer M, Sweeney DA, Torres A, Waterer G, Kalil AC. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. Intensive Care Med. 2023;49(2):142\u201353.","journal-title":"Intensive Care Med"},{"issue":"10","key":"9544_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.21037\/atm.2017.04.04","volume":"5","author":"D Nora","year":"2017","unstructured":"Nora D, Salluh J, Martin-Loeches I, P\u00f3voa P. Biomarker-guided antibiotic therapy-strengths and limitations. Ann Transl Med. 2017;5(10):208.","journal-title":"Ann Transl Med"},{"issue":"1","key":"9544_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13054-020-02946-y","volume":"24","author":"I Borges","year":"2020","unstructured":"Borges I, Carneiro R, Bergo R, et al. Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers. Crit Care. 2020;24(1):281.","journal-title":"Crit Care"},{"key":"9544_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-319-04220-6_2","volume":"161","author":"TR Zembower","year":"2014","unstructured":"Zembower TR. Epidemiology of infections in cancer patients. Cancer Treat Res. 2014;161:43\u201389. https:\/\/doi.org\/10.1007\/978-3-319-04220-6_2.","journal-title":"Cancer Treat Res"},{"issue":"1","key":"9544_CR12","doi-asserted-by":"publisher","first-page":"6983","DOI":"10.1007\/s40121-017-0146-1","volume":"6","author":"KV Rolston","year":"2017","unstructured":"Rolston KV. Infections in Cancer Patients with Solid Tumors: A Review. Infect Dis Ther. 2017;6(1):6983. https:\/\/doi.org\/10.1007\/s40121-017-0146-1.","journal-title":"Infect Dis Ther"},{"issue":"10","key":"9544_CR13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1097\/CCM.0b013e31828e969f","volume":"41","author":"CF Oliveira","year":"2013","unstructured":"Oliveira CF, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med. 2013;41(10):2336\u201343.","journal-title":"Crit Care Med"},{"issue":"7","key":"9544_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EMW, de Smet AMGA, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(16)00053-0. (Epub 2016 Mar 2 PMID: 26947523).","journal-title":"Lancet Infect Dis"},{"key":"9544_CR15","doi-asserted-by":"publisher","unstructured":"Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, R\u00e9gnier B, Brun-Buisson C, Chastre J, Wolff M; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(09)61879-1. Epub 2010 Jan 25. PMID: 20097417.","DOI":"10.1016\/S0140-6736(09)61879-1"},{"issue":"12","key":"9544_CR16","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1086\/430382","volume":"40","author":"P P\u00f3voa","year":"2005","unstructured":"P\u00f3voa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. Pilot study evaluating C-reactive protein levels in the assessment of response to treatment of severe bloodstream infection. Clin Infect Dis. 2005;40(12):1855\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"9544_CR17","first-page":"210","volume":"12","author":"X Schmit","year":"2008","unstructured":"Schmit X, Vincent JL, Dach FV. Practical application of C-reactive protein in critically ill patients. Crit Care. 2008;12(3):210.","journal-title":"Crit Care"},{"issue":"21","key":"9544_CR18","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","volume":"323","author":"E Von Dach","year":"2020","unstructured":"Von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, Harbarth S. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment, on 30-day clinical failure rate in patients with uncomplicated Gram-negative bacteremia: a randomized clinical trial. JAMA. 2020;323(21):2160\u20139.","journal-title":"JAMA"},{"issue":"1","key":"9544_CR19","first-page":"31","volume":"29","author":"LS Rabello","year":"2017","unstructured":"Rabello LS, Silva JR, Silva RL, Oliveira JR, Rabello LS, Silva JR, Rabello LS. The prognostic value of C-reactive protein in critically ill patients with cancer and sepsis. Brazilian Journal of Intensive Care. 2017;29(1):31\u20136.","journal-title":"Brazilian Journal of Intensive Care"},{"issue":"12","key":"9544_CR20","first-page":"1075","volume":"16","author":"H El Haddad","year":"2018","unstructured":"El Haddad H, Chaftari AM, Hachem R, Raad I. Biomarkers of sepsis and bloodstream infections: the role of procalcitonin and C-reactive protein. Expert Rev Anti Infect Ther. 2018;16(12):1075\u201381.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"9544_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874828701407010001","volume":"7","author":"CF Oliveira","year":"2014","unstructured":"Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC. The role of procalcitonin in early diagnosis of sepsis in oncology patients. The Open Crit Care Med Journal. 2014;7(1):1\u20136.","journal-title":"The Open Crit Care Med Journal"},{"issue":"8","key":"9544_CR22","first-page":"805","volume":"26","author":"H Takahashi","year":"2020","unstructured":"Takahashi H, Nomura Y, Nakanishi N, Fujimoto Y, Iwagami M, Tanaka H, Nakahara T. The clinical impact of antimicrobial stewardship program on patients with sepsis or septic shock in a tertiary hospital. Journal of Infection and Chemotherapy. 2020;26(8):805\u201311.","journal-title":"Journal of Infection and Chemotherapy"},{"issue":"1","key":"9544_CR23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40560-022-00598-4","volume":"10","author":"K Kenjikubo","year":"2022","unstructured":"Kenjikubo K, Wada K, Masui H, Shiroyama T. Duration of antibiotic therapy and clinical outcomes in patients with bloodstream infections: a systematic review and meta-analysis. J Intensive Care. 2022;10(1):7.","journal-title":"J Intensive Care"},{"issue":"12","key":"9544_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0143080.PMID:26717416;PMCID:PMC4705106","volume":"10","author":"S Shrotriya","year":"2015","unstructured":"Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS ONE. 2015;10(12): e0143080. https:\/\/doi.org\/10.1371\/journal.pone.0143080.PMID:26717416;PMCID:PMC4705106.","journal-title":"PLoS ONE"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09544-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09544-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09544-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T14:03:29Z","timestamp":1726236209000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09544-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9544"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09544-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the institution's Research Ethics Committee (CAAE: 39519720.8.0000.5149). Due to the retrospective design, the application of an Informed Consent Form was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"974"}}